Menarini Ricerche

Menarini Ricerche is the dedicated research and development arm of the Menarini Group, Italy's largest pharmaceutical company. The organization focuses on the discovery and clinical development of innovative therapeutic solutions, with a primary concentration on oncology and inflammation. Its pipeline includes a diverse range of modalities, including small molecules, monoclonal antibodies, and antibody-drug conjugates. A significant milestone for the company was the development of elacestrant, the first oral selective estrogen receptor degrader (SERD) approved for ER+/HER2- advanced breast cancer. Menarini Ricerche operates major R&D centers in Italy and Germany, collaborating extensively with academic and industrial partners to advance its clinical programs.